Executive Team

The AVEO Oncology management team comprises executives with years of oncology and pharmaceutical industry experience and expertise, and a proven track record for success in bringing important new therapies to patients.

  • Michael P. Bailey

    PRESIDENT AND CEO

    Michael P. Bailey

    Michael P. Bailey serves as president and chief executive officer of AVEO and a member of the company’s board of directors, bringing more than 20 years of experience in the pharmaceutical industry to the company. He joined AVEO in 2010 as the company’s chief commercial officer, was named chief business officer in 2013 and assumed his current roles in January 2015. Mr. Bailey joined AVEO from Synta Pharmaceuticals, where he served as senior vice president, business development, and chief commercial officer since 2008. Prior to joining Synta, Mr. Bailey led ImClone Systems' (now Eli Lilly) Worldwide Commercial Organization. During his nine year tenure at ImClone, he was responsible for commercial aspects of the planning and launch of ERBITUX® (cetuximab) across multiple oncology indications, as well as new product planning for the ImClone development portfolio, which included CYRAMZA® (ramucirumab) and necitumumab. In addition, Mr. Bailey was a key member of the strategic leadership committees for ImClone and its North American and worldwide partnerships. Prior to joining ImClone, Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc., and was a key member of their global commercial partnership teams. Mr. Bailey started his career in the pharmaceutical industry as part of SmithKline Beecham's Executive Marketing Development Program, where he held a variety of commercial roles, including sales, strategic planning, and product management. Mr. Bailey received a B.S. in psychology from St. Lawrence University and an M.B.A. in international marketing from the Mendoza College of Business at University of Notre Dame.

  • Michael N. Needle, M.D.

    CHIEF MEDICAL OFFICER

    Michael N. Needle, M.D.

    Michael N. Needle, M.D., serves as chief medical officer of AVEO, and brings more than 15 years of pharmaceutical industry experience in drug development and regulatory affairs. This includes central roles in the development of oncology and hematology drugs, including Erbitux® (cetuximab), Revlimid® (lenalidomide) and Pomalyst® (pomolidimide). He most recently served as the Chief Medical Officer of Array BioPharma. Prior to Array, Dr. Needle was Chief Medical Officer of the Multiple Myeloma Research Foundation and Consortium (MMRF). Prior to MMRF, he held multiple Vice President level positions at Celgene in Clinical Research and Development in Oncology, Strategic Medical Business Development, and Pediatric Strategy. Dr. Needle also served as the Vice President of Clinical Affairs at ImClone Systems Incorporated. Dr. Needle did his fellowship in Pediatric Hematology / Oncology at the Children's Hospital Medical Center and the Fred Hutchinson Cancer Research Center of the University of Washington in Seattle and the University of Texas M.D. Anderson Cancer Center in Houston. Dr. Needle has held faculty positions at the University of Pennsylvania and Columbia University. Dr. Needle graduated from Binghamton University with a Bachelor of Arts in Physics and received his medical degree from SUNY Downstate Medical Center, in Brooklyn, New York.

  • Keith S. Ehrlich, C.P.A.

    CHIEF FINANCIAL OFFICER

    Keith S. Ehrlich, C.P.A.

    Keith S. Ehrlich, C.P.A., serves as chief financial officer of AVEO. He most recently served as Chief Financial Officer of Synta Pharmaceuticals. Prior to Synta, Mr. Ehrlich served in various senior finance and audit roles, including Chief Financial Officer of Argentys, Dyax and OraVax, Director of Finance of Vertex Pharmaceuticals and senior audit manager with PricewaterhouseCoopers, LLP. Mr. Ehrlich received his B.A. in Biology from Drew University and his M.B.A. in Finance and Accounting from Rutgers University.

  • Michael Boretti, Ph.D.

    VICE PRESIDENT, CORPORATE DEVELOPMENT AND ALLIANCE MANAGEMENT

    Michael Boretti, Ph.D.

    Michael Boretti serves as the Company’s Vice President of Corporate Development and Alliance Management, having joined AVEO in 2008 and bringing 10 years of business and strategy experience in the biopharmaceutical industry. While at AVEO, Dr. Boretti has lead strategic planning and business development activities, successfully establishing and managing licensing and collaboration agreements across several R&D programs. More recently, he has also served as program and alliance manager for tivozanib program. Prior to joining AVEO, Michael worked for three years as a strategy consultant in the Biopharma and Life Sciences Practice at L.E.K. Consulting. During his time at L.E.K., Michael completed more than 15 projects for biotech and pharmaceutical industry clients, providing strategic advice in the areas of business development, M&A transactions, product strategy, market assessments, and corporate planning. Dr. Boretti received a B.S. in Engineering Science with a minor in Biomedical Engineering from the University of Virginia, and a Ph.D. in Bioengineering from the University of Pennsylvania.

  • Emile Farhan, Ph.D.

    VICE PRESIDENT, TECHNICAL OPERATIONS

    Emile Farhan, Ph.D.

    Emile Farhan has more than 20 years of experience in the pharmaceutical industry. As the Vice President of Technical Operations, he leads all aspects of chemistry, manufacturing and control of AVEO programs. He joined AVEO in April 2012 after his tenure at Eisai, where he served as the Head of CMC Global Operations Coordination for the US and Europe and as the Director of Pharmaceutical Development at MGI prior to its acquisition by Eisai. Prior to MGI, he served as the Senior Director of Product Development and Manufacturing at Mersana Therapeutics. Dr. Farhan also held several leadership roles at Pharm-Eco from 1992 until its acquisition by Johnson Matthey in 2000 and at Johnson Matthey Pharma from 2000 to 2006, where he was the Senior Director of Technical Operations and Scientific Affairs. Dr. Farhan holds a Ph.D. from Brandeis University and an MS from the University of Massachusetts.